JOINN Laboratories (China) Co., Ltd. Class H (HK:6127)
:6127
Top Page
JOINN Laboratories (China) Co., Ltd. Class H
(6127)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$22.50
▲(6.53% Upside)
Action:ReiteratedDate:04/02/26
The score is primarily supported by strong balance-sheet strength (minimal debt) and positive free cash flow, offset by severe recent revenue contraction and inconsistent cash conversion. Technical indicators are mixed (negative MACD but moderately constructive RSI/stochastic), while valuation is also mixed with a high P/E partially balanced by a very high dividend yield.
Positive Factors
Balance-sheet strength
Extremely low leverage and a large equity base materially reduce financial distress risk. This conservative capitalization supports sustained operations, funds discretionary investment or buybacks, and preserves strategic optionality during multi-quarter revenue weakness or industry cyclicality.
Negative Factors
Severe revenue contraction
A dramatic two-year top-line decline sharply reduces scale economics and threatens long-run client relationships. Sustained or recurring revenue drops impair capacity utilization, pressure per-study pricing, and make multi-quarter recovery uncertain absent clear new contract wins.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Extremely low leverage and a large equity base materially reduce financial distress risk. This conservative capitalization supports sustained operations, funds discretionary investment or buybacks, and preserves strategic optionality during multi-quarter revenue weakness or industry cyclicality.
Read all positive factors
JOINN Laboratories (China) Co., Ltd. Class H (6127) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$28.49B
Dividend Yield0.15%
Average Volume (3M)6.46M
Price to Earnings (P/E)46.3
Beta (1Y)1.40
Revenue Growth-21.76%
EPS GrowthN/A
CountryHK
Employees2,510
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.34
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.80Price Target Upside-20.45% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)0.57
Revenue Forecast (FY)HK$2.13B
JOINN Laboratories (China) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Relat...
How the Company Makes Money
JOINN Laboratories (China) Co., Ltd. primarily makes money by charging customers (pharma, biotech, and medical device companies) service fees under contract research arrangements for outsourced R&D work. Key revenue streams typically include (i) n...
JOINN Laboratories (China) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
90
Very Positive
Cash Flow
66
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.66B | 2.02B | 2.38B | 2.27B | 1.52B |
| Gross Profit | 343.31M | 573.77M | 1.01B | 1.09B | 739.12M |
| EBITDA | 483.24M | 234.36M | 639.52M | 1.36B | 738.86M |
| Net Income | 297.84M | 74.08M | 396.99M | 1.07B | 557.46M |
Balance Sheet | |||||
| Total Assets | 9.68B | 9.40B | 10.03B | 10.36B | 8.54B |
| Cash, Cash Equivalents and Short-Term Investments | 2.63B | 2.36B | 4.77B | 3.33B | 4.84B |
| Total Debt | 1.42M | 21.60M | 41.92M | 87.71M | 95.32M |
| Total Liabilities | 1.36B | 1.32B | 1.75B | 2.17B | 1.39B |
| Stockholders Equity | 8.32B | 8.08B | 8.28B | 8.18B | 7.14B |
Cash Flow | |||||
| Free Cash Flow | 300.96M | 69.54M | 430.15M | 696.23M | 448.41M |
| Operating Cash Flow | 444.57M | 338.93M | 622.88M | 971.07M | 685.66M |
| Investing Cash Flow | -419.19M | -1.96B | -315.43M | -2.16B | -2.07B |
| Financing Cash Flow | -66.98M | -265.63M | -361.68M | -99.33M | 5.29B |
JOINN Laboratories (China) Co., Ltd. Class H Technical Analysis
Positive
21.12
Price Trends
20.75
Positive
20.48
Positive
20.81
Positive
Market Momentum
-0.02
Negative
60.31
Neutral
81.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6127, the sentiment is Positive. The current price of 21.12 is above the 20-day moving average (MA) of 18.70, above the 50-day MA of 20.75, and above the 200-day MA of 20.81, indicating a bullish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 60.31 is Neutral, neither overbought nor oversold. The STOCH value of 81.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6127.
JOINN Laboratories (China) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | HK$350.05B | 13.23 | 23.81% | 1.84% | 11.55% | 64.46% | |
72 Outperform | HK$22.30B | 14.57 | 24.01% | 0.63% | 13.58% | 24.59% | |
66 Neutral | HK$28.49B | 46.26 | 3.65% | 0.15% | -21.76% | ― | |
58 Neutral | HK$48.58B | 37.05 | 4.27% | 0.80% | -3.81% | -34.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$4.13B | -10.14 | -32.79% | ― | 29639.67% | 23.30% |
* Healthcare Sector Average
HK:6127
JOINN Laboratories (China) Co., Ltd. Class H
21.22
10.56
99.06%
HK:3347
Hangzhou Tigermed Consulting Co., Ltd. Class H
42.62
17.62
70.49%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
44.00
22.29
102.67%
HK:2359
WuXi AppTec Co., Ltd. Class H
124.60
77.43
164.15%
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
5.06
0.14
2.85%
JOINN Laboratories (China) Co., Ltd. Class H Corporate Events
JOINN Laboratories Profit Jumps on Fair-Value Gains Despite Revenue Decline in 2025
Mar 30, 2026
JOINN Laboratories reported audited 2025 results showing revenue of RMB1.66 billion, down 17.9% year-on-year, and gross profit of RMB281.06 million, a 44.4% decline, reflecting weaker top-line performance and margin pressure in its research servic...
JOINN Laboratories Announces Final 2025 Cash Dividend and Tax Treatment for H Shareholders
Mar 30, 2026
JOINN Laboratories (China) Co., Ltd. has announced a proposed final cash dividend of RMB 0.12 per share for the financial year ended 31 December 2025, with payment to eligible shareholders expected by no later than 31 August 2026. The dividend wil...
JOINN Laboratories Overhauls Governance Rules and Adds Non-Executive Director
Mar 30, 2026
JOINN Laboratories (China) Co., Ltd. has announced a package of corporate governance changes, including proposed amendments to its Articles of Association and the rules of procedures for shareholders’ general meetings, as well as the nominat...
JOINN Laboratories Sets March 2026 Board Meeting to Approve 2025 Results
Mar 18, 2026
JOINN Laboratories (China) Co., Ltd. has scheduled a board meeting for 30 March 2026 to review and approve the group’s annual results for the financial year ended 31 December 2025. The board will also consider recommending a final dividend f...
JOINN Laboratories’ CITIC Product Holdings Reach RMB460 Million, Triggering Discloseable Transaction
Mar 16, 2026
JOINN Laboratories has increased its investments in financial products issued by CITIC Securities and its subsidiaries, with the aggregate outstanding investment now reaching RMB460 million as of 16 March 2026. The company states that all earlier ...
JOINN Laboratories Warns of 2025 Revenue Drop but Predicts Profit Surge on Biological Asset Gains
Jan 20, 2026
JOINN Laboratories (China) Co., Ltd. has issued a profit warning for 2025, flagging that revenue is expected to fall by about 13.9% to 22.1% year on year to roughly RMB1.57 billion–RMB1.74 billion, reflecting weaker performance in its core l...
JOINN Laboratories Details 2026 Caps for Connected R&D and BioAI Service Deals
Jan 12, 2026
JOINN Laboratories (China) Co., Ltd. has issued a supplemental announcement detailing how it set the 2026 annual cap of RMB47 million for continuing connected transactions with Staidson under their research and development service framework agreem...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.